723 related articles for article (PubMed ID: 26366058)
1. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
2. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
[TBL] [Abstract][Full Text] [Related]
4. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
[TBL] [Abstract][Full Text] [Related]
6. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study.
Kvols LK; Oberg KE; O'Dorisio TM; Mohideen P; de Herder WW; Arnold R; Hu K; Zhang Y; Hughes G; Anthony L; Wiedenmann B
Endocr Relat Cancer; 2012 Oct; 19(5):657-66. PubMed ID: 22807497
[TBL] [Abstract][Full Text] [Related]
7. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E
Lancet Oncol; 2017 Dec; 18(12):1652-1664. PubMed ID: 29074099
[TBL] [Abstract][Full Text] [Related]
9. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
[TBL] [Abstract][Full Text] [Related]
10. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
Colao A; Bronstein MD; Freda P; Gu F; Shen CC; Gadelha M; Fleseriu M; van der Lely AJ; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Sheppard M;
J Clin Endocrinol Metab; 2014 Mar; 99(3):791-9. PubMed ID: 24423324
[TBL] [Abstract][Full Text] [Related]
11. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
12. Long-acting formulations of somatostatin analogues.
Anthony LB
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.
Pavel ME; Baudin E; Öberg KE; Hainsworth JD; Voi M; Rouyrre N; Peeters M; Gross DJ; Yao JC
Ann Oncol; 2017 Jul; 28(7):1569-1575. PubMed ID: 28444114
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
Wolin EM; Hu K; Hughes G; Bouillaud E; Giannone V; Resendiz KH
Cancer Chemother Pharmacol; 2013 Aug; 72(2):387-95. PubMed ID: 23765178
[TBL] [Abstract][Full Text] [Related]
15. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
Sheppard M; Bronstein MD; Freda P; Serri O; De Marinis L; Naves L; Rozhinskaya L; Hermosillo Reséndiz K; Ruffin M; Chen Y; Colao A
Pituitary; 2015 Jun; 18(3):385-94. PubMed ID: 25103549
[TBL] [Abstract][Full Text] [Related]
16. Pasireotide: a novel treatment for patients with acromegaly.
Cuevas-Ramos D; Fleseriu M
Drug Des Devel Ther; 2016; 10():227-39. PubMed ID: 26811671
[TBL] [Abstract][Full Text] [Related]
17. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
Shen C; Shih YC; Xu Y; Yao JC
Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
[TBL] [Abstract][Full Text] [Related]
18. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
[TBL] [Abstract][Full Text] [Related]
19. An update of lanreotide acetate for treatment of adults with carcinoid syndrome.
Guadalupe E; Deshpande HA; Stein SM
Drugs Today (Barc); 2018 Aug; 54(8):457-465. PubMed ID: 30209440
[TBL] [Abstract][Full Text] [Related]
20. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]